Clinical trials: Light Chain (AL) Amyloidosis
AL Amyloidosis
A EUropean REgistry and Sample Sharing networK to Promote the Diagnosis and Management of Light Chain Amyloidosis (EUREKA)
A prospective patients' registry collecting all new cases of AL amyloidosis evaluated at referral Centers from across Europe and a sample sharing network will be created to study mechanisms of the disease through the use of…
- Trial name
- EUREKA (NCT06205953)
- Where
- 6 sites in Germany, Italy and 4 more
- Volunteers
- 400 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
AL Amyloidosis
Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis
Light chain (AL) amyloidosis is a bone marrow disorder that affects a wide range of organs that can lead to organ dysfunction and death.
- Trial name
- NCT03236792
- Testing
- Ixazomib, Cyclophosphamide, Dexamethasone
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Cardiac Amyloidosis
REVEAL - Research With I-124 EVuzamitide to Elucidate Cardiac AmyLoidosis
The purpose of this multicenter, open-label, single-arm, single-dose study is to assess the sensitivity and specificity of I-124 evuzamitide for the diagnosis of cardiac amyloidosis compared to current clinical standards for…
- Trial name
- REVEAL (NCT06788535)
- Testing
- I-124 evuzamitide
- Where
- 20 sites in United States
- Volunteers
- 204 people
- Sponsor
- Sharmila Dorbala
AL Amyloidosis
Radioimmunoimaging of Light Chain (AL) Amyloidosis
The purpose of the study is to determine the capability of a radiolabeled amyloid-reactive monoclonal antibody (mAb) to document the presence and distribution of amyloid deposits by PET/CT imaging in patients with AL amyloidosis.
- Trial name
- NCT01815086
- Testing
- Single infusion of 124I-labeled anti-amyloid mAb 11-1F4: 2 mCi (1 mg)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Tennessee
Amyloidosis; Systemic
A Study to Characterize the Biodistribution of 124I-Labeled AT-03 in Patients With Systemic Amyloidosis
This is a single center Phase 1 study is to evaluate the biodistribution of radiolabeled AT-03 in patients with systemic amyloidosis.
- Trial name
- AT03-001 (NCT05201911)
- Testing
- 124I-AT03
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Attralus, Inc.
Light Chain (AL) Amyloidosis, Cardiac Involvement
A Trial for the Treatment of Cardiac AL-Amyloidosis With the Green Tea Compound Epigallocatechin-3-gallate (TAME-AL)
Efficacy and safety of epigallocatechin-3-gallate (EGCG) in patients with cardiac amyloid light-chain (AL) amyloidosis. Evaluation of clinical efficacy of EGCG intake using a pretest posttest comparison of left ventricular…
- Trial name
- TAME-AL (NCT02015312)
- Testing
- Epigallocatechin-3-gallate (EGCG)
- Where
- Germany
- Volunteers
- 38 people
- Sponsor
- Florian Michel
AL Amyloidosis
Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis
The study is being done to see if the combination of bendamustine and dexamethasone will help people with amyloidosis that has returned after standard treatment, and to to estimate the partial hematologic response rate (PHR).
- Trial name
- NCT01222260
- Testing
- Bendamustine, Dexamethasone
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- Columbia University
Light Chain Amyloidosis
FKC288 for Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
This study is a single-center exploratory clinical trial. It is estimated that 6-12 subjects will be enrolled. The "BOIN" dose escalation design is adopted.
- Trial name
- NCT05978661
- Testing
- FKC288
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Nanjing University School of Medicine
Newly Diagnosed Amyloidosis, Amyloidosis Stage I-IIIA
Linvoseltamab Versus Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-Vcd) in Adult Participants With Newly Diagnosed Systemic Light Chain Amyloidosis
This study is researching a Regeneron drug called linvoseltamab ("study drug") alone compared to standard of care (SoC) combination to see if it can help treat participants who are newly diagnosed and previously untreated for…
- Trial name
- LINKER-AL1 (NCT07901725)
- Testing
- Linvoseltamab, Daratumumab, Bortezomib
- Volunteers
- 382 people
- Sponsor
- Regeneron Pharmaceuticals
Multiple Myeloma, Amyloidosis
Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.
Captisol Enabled Melphalan, is a new formulation of the standard of care melphalan chemotherapy that in packaged in an inactive substance that is believed to help the chemotherapy be more stable (meaning that it doesn't lose its…
- Trial name
- NCT02909036
- Testing
- Melphalan, Pegfilgrastim, Autologous Hematopoietic Progenitor Cell Transplant
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Plasma Cell Dyscrasias, Monoclonal Gammopathy of Undetermined Significance
Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
The investigators are researching patients with diseases of their plasma cells in order to improve their quality and length of life.
- Conditions
- Plasma Cell Dyscrasias, Monoclonal Gammopathy of Undetermined Significance, AL Amyloidosis, Multiple Myeloma
- Trial name
- B-SCR-MM (NCT01408225)
- Testing
- tissue banking
- Where
- United States
- Volunteers
- 5,000 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
AL Amyloidosis
A Pilot Study of Anselamimab in Patients With AL Amyloidoma and Measurable Tissue Involvement
This is an exploratory study to assess the binding of CAEL-101/anselamimab to amyloid in vivo, recruitment of inflammatory cells and reduction of the amyloid mass.
- Trial name
- NCT07615270
- Testing
- Anselamimab
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Stanford University
Amyloidosis
Bortezomib and Dexamethasone Followed by ASCT Compared With ASCT Alone in Treating Patients With AL Amyloidosis
This randomized phase III trial is studying the side effects and how well giving induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation (ASCT) compared with ASCT alone in treating…
- Trial name
- NCT01998503
- Testing
- Bortezomib, dexamethasone, filgrastim
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Nanjing University School of Medicine
AL Amyloidosis
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)
AL (or light chain) amyloidosis begins in the bone marrow where abnormal proteins misfold and create free light chains that cannot be broken down.
- Trial name
- NCT04512235
- Testing
- CAEL-101, cyclophosphamide, bortezomib, and dexamethasone (CyBorD) regimen
- Where
- 110 sites in United States, Australia and 17 more
- Volunteers
- 281 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
AL Amyloidosis, Multiple Myeloma
SMS-Based Remote Symptom Monitoring for Patients With Plasma Cell Disorders
This study evaluates whether daily SMS-based (text messages) symptom monitoring is feasible and acceptable in patients who are undergoing treatment for multiple myeloma (MM) or systemic light chain amyloidosis (AL), and whether…
- Trial name
- NCT07850284
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Mayo Clinic
Primary Systemic Amyloidosis
Lendexal in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed
Primary outcome measure: Hematologic response rate to the association of Lenalidomide, Cyclophosphamide and Dexamethasone. Secondary outcome measures: Organ response rate.
- Trial name
- LENDEXAL (NCT01194791)
- Testing
- Lenalidomide, Cyclophosphamide, Dexamethasone
- Where
- 10 sites in Spain
- Volunteers
- 30 people
- Sponsor
- PETHEMA Foundation
Multiple Myeloma, Plasma Cell Myeloma
S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis
RATIONALE: Drugs used in chemotherapy such as melphalan work in different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00064337
- Testing
- filgrastim, cyclophosphamide, dexamethasone
- Where
- 35 sites in United States
- Volunteers
- 104 people
- Sponsor
- SWOG Cancer Research Network
Primary Amyloidosis of Light Chain Type
Epigallocatechingallate (EGCG) in Cardiac AL Amyloidosis
In a proportion of patients with AL amyloidosis there is no improvement of cardiac function despite hematologic response to treatment.
- Trial name
- EpiCardiAL (NCT01511263)
- Testing
- Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhithmias), Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhythmias) plus EGCG
- Where
- Italy
- Volunteers
- 86 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Systemic AL Amyloidosis
Rapid dFLC Response Predict CHR in AL Amyloidosis
Light chain amyloidosis (AL amyloidosis) is a rare plasma cell dyscrasia characterized by the deposition of insoluble amyloid fibrils in multiple organ systems.
- Trial name
- NCT06627309
- Testing
- Dara IV, Bortezomib (drug), Dexamethasone
- Where
- 8 sites in China
- Volunteers
- 50 people
- Sponsor
- Peking University People's Hospital
Amyloidosis, AL Amyloidosis
BE.Amycon Biobank & Data Registry UZ Leuven
The goal of this study is to collect and store human body material (HBM) of patients with amyloidosis in a biobank "BE.Amycon biobank" for future research and to collect clinical data of patients with amyloidosis in a database…
- Conditions
- Amyloidosis, AL Amyloidosis, Amyloidosis Cardiac
- Trial name
- NCT07172243
- Where
- 2 sites in Belgium
- Volunteers
- 505 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven